These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 35702041)

  • 41. Hijacking Methyl Reader Proteins for Nuclear-Specific Protein Degradation.
    Nalawansha DA; Li K; Hines J; Crews CM
    J Am Chem Soc; 2022 Mar; 144(12):5594-5605. PubMed ID: 35311258
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimization of Potent Ligands for the E3 Ligase DCAF15 and Evaluation of Their Use in Heterobifunctional Degraders.
    Lucas SCC; Ahmed A; Ashraf SN; Argyrou A; Bauer MR; De Donatis GM; Demanze S; Eisele F; Fusani L; Hock A; Kadamur G; Li S; Macmillan-Jones A; Michaelides IN; Phillips C; Rehnström M; Richter M; Rodrigo-Brenni MC; Shilliday F; Wang P; Storer RI
    J Med Chem; 2024 Apr; 67(7):5538-5566. PubMed ID: 38513086
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Delivering on Cell-Selective Protein Degradation Using Chemically Tailored PROTACs.
    Yao R; Luo T; Wang M
    Chembiochem; 2023 Oct; 24(19):e202300413. PubMed ID: 37496112
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recent Advances in PROTAC Technology Toward New Therapeutic Modalities.
    Yokoo H; Naganuma M; Oba M; Demizu Y
    Chem Biodivers; 2022 Nov; 19(11):e202200828. PubMed ID: 36124821
    [TBL] [Abstract][Full Text] [Related]  

  • 45. E3 ligase ligand chemistries: from building blocks to protein degraders.
    Sosič I; Bricelj A; Steinebach C
    Chem Soc Rev; 2022 May; 51(9):3487-3534. PubMed ID: 35393989
    [TBL] [Abstract][Full Text] [Related]  

  • 46. What influences the activity of Degrader-Antibody conjugates (DACs).
    Guo Y; Li X; Xie Y; Wang Y
    Eur J Med Chem; 2024 Mar; 268():116216. PubMed ID: 38387330
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comprehensive review of BET-targeting PROTACs for cancer therapy.
    Zhou XL; Zhao F; Xu YT; Guan YY; Yu T; Zhang YZ; Duan YC; Zhao Y
    Bioorg Med Chem; 2022 Nov; 73():117033. PubMed ID: 36202064
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation.
    Chen Y; Tandon I; Heelan W; Wang Y; Tang W; Hu Q
    Chem Soc Rev; 2022 Jul; 51(13):5330-5350. PubMed ID: 35713468
    [TBL] [Abstract][Full Text] [Related]  

  • 49. N-Heterocycle based Degraders (PROTACs) Manifesting Anticancer Efficacy: Recent Advances.
    Banerjee S; Sharma S; Thakur A; Sachdeva R; Sharma R; Nepali K; Liou JP
    Curr Drug Targets; 2023; 24(15):1184-1208. PubMed ID: 37946353
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of reversible and irreversible covalent chemistry in targeted protein degradation.
    Kiely-Collins H; Winter GE; Bernardes GJL
    Cell Chem Biol; 2021 Jul; 28(7):952-968. PubMed ID: 33789091
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PROTAC-DB: an online database of PROTACs.
    Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
    Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nano Proteolysis Targeting Chimeras (PROTACs) with Anti-Hook Effect for Tumor Therapy.
    Zhang NY; Hou DY; Hu XJ; Liang JX; Wang MD; Song ZZ; Yi L; Wang ZJ; An HW; Xu W; Wang H
    Angew Chem Int Ed Engl; 2023 Sep; 62(37):e202308049. PubMed ID: 37486792
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.
    Burslem GM; Smith BE; Lai AC; Jaime-Figueroa S; McQuaid DC; Bondeson DP; Toure M; Dong H; Qian Y; Wang J; Crew AP; Hines J; Crews CM
    Cell Chem Biol; 2018 Jan; 25(1):67-77.e3. PubMed ID: 29129716
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cancer Selective Target Degradation by Folate-Caged PROTACs.
    Liu J; Chen H; Liu Y; Shen Y; Meng F; Kaniskan HÜ; Jin J; Wei W
    J Am Chem Soc; 2021 May; 143(19):7380-7387. PubMed ID: 33970635
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeted protein degradation: Emerging concepts and protein state-specific targeting principles.
    Tao AJ; Gadbois GE; Buczynski SA; Ferguson FM
    Curr Opin Chem Biol; 2022 Apr; 67():102114. PubMed ID: 35042023
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The impact of E3 ligase choice on PROTAC effectiveness in protein kinase degradation.
    Sobierajski T; Małolepsza J; Pichlak M; Gendaszewska-Darmach E; Błażewska KM
    Drug Discov Today; 2024 Jul; 29(7):104032. PubMed ID: 38789027
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Proteasomal Degradation of Zn-Dependent Hdacs: The E3-Ligases Implicated and the Designed Protacs That Enable Degradation.
    Márquez-Cantudo L; Ramos A; Coderch C; de Pascual-Teresa B
    Molecules; 2021 Sep; 26(18):. PubMed ID: 34577077
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early evaluation of opportunities in oral delivery of PROTACs to overcome their molecular challenges.
    Yang W; Saboo S; Zhou L; Askin S; Bak A
    Drug Discov Today; 2024 Feb; 29(2):103865. PubMed ID: 38154757
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Target protein degradation by protacs: A budding cancer treatment strategy.
    Choudhary D; Kaur A; Singh P; Chaudhary G; Kaur R; Bayan MF; Chandrasekaran B; Marji SM; Ayman R
    Pharmacol Ther; 2023 Oct; 250():108525. PubMed ID: 37696366
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fluorescence theranostic PROTACs for real-time visualization of ERα degradation.
    Wang X; Xin L; Deng X; Dong C; Hu G; Zhou HB
    Eur J Med Chem; 2024 Mar; 267():116184. PubMed ID: 38320426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.